Related Experiment Video
Updated: Sep 2, 2025
Murine Cervical Heart Transplantation Model Using a Modified Cuff Technique
Published on: October 12, 2014
BEZ235 Prolongs Murine Cardiac Allograft Survival Through the Autophagy Pathway
Xiaolong Miao1, Yuancong Jiang1, Zelai Wu1
1Department of General Surgery, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China.
Background:
BEZ235, a dual PI3K/mTOR inhibitor, has shown a critical impact in the treatment of cancers, with the ability to induce autophagy. However, the effects of BEZ235 in heart transplant have been rarely investigated. The aim of this study was to evaluate the potency of BEZ235 in cardiac allograft survival.
Methods:
BEZ235 was administered during the perioperative period of syngeneic or allogeneic heart transplant to assess survival time. Next, the autophagy signaling pathway and the proinflammatory cytokines were analyzed. Furthermore, a cardiomyocytes-specific ATG5 gene-ablated mouse was used to confirm the results.
Results:
BEZ235 treatment significantly prolonged the survival of the cardiac graft and reduced the infiltration of inflammatory cells. The expression levels of autophagy proteins were increased in the BEZ235 treatment group compared to the control group, but the therapeutic effect of BEZ235 was weakened in the cardiomyocytes-specific ATG5 gene-ablated mice. Moreover, BEZ235 significantly downregulated the expression of IL-1β, IL-2, and TNF-α.
Conclusions:
It seems BEZ235 could induce autophagy and prolonged murine cardiac allograft survival in a mechanism that involved the autophagy pathway and changed multiple inflammatory factors. This study has proposed a theoretical foundation for the strong connection between mTOR-induced autophagy and heart transplant.
Insights
BEZ235, a dual PI3K/mTOR inhibitor, significantly extended cardiac allograft survival by inducing autophagy and reducing inflammation. This suggests a new therapeutic avenue for heart transplant patients by targeting the mTOR-induced autophagy pathway.
Area of Science:
- Immunology
- Pharmacology
- Cell Biology
Background:
- BEZ235 is a dual PI3K/mTOR inhibitor with known anticancer and autophagy-inducing properties.
- The impact of BEZ235 on heart transplantation outcomes remains largely unexplored.
- This study investigates BEZ235's potential to improve cardiac allograft survival.
Purpose of the Study:
- To evaluate the efficacy of BEZ235 in prolonging cardiac allograft survival.
- To elucidate the role of autophagy and inflammation in BEZ235's therapeutic effects.
- To establish a mechanistic link between mTOR-induced autophagy and heart transplantation.
Main Methods:
- BEZ235 administered perioperatively in syngeneic and allogeneic heart transplant models.
- Analysis of autophagy signaling pathway and pro-inflammatory cytokine expression.
- Utilized cardiomyocytes-specific ATG5 gene-ablated mice to confirm autophagy-dependent mechanisms.
Main Results:
- BEZ235 treatment significantly enhanced cardiac allograft survival and decreased inflammatory cell infiltration.
- Increased autophagy protein expression observed in BEZ235-treated group.
- Therapeutic benefits of BEZ235 were diminished in ATG5-ablated mice, confirming autophagy's role.
- BEZ235 markedly reduced IL-1β, IL-2, and TNF-α expression.
Conclusions:
- BEZ235 promotes cardiac allograft survival through autophagy induction and modulation of inflammatory factors.
- The study provides a theoretical basis for the connection between mTOR-induced autophagy and heart transplantation.
- BEZ235 demonstrates potential as a novel therapeutic agent in cardiac transplantation.
